The Board and CEO of Emotra AB (publ) hereby present the interim report for the first quarter 2019. 190515 Interim report Jan-March 2019
Emotra AB (publ) Interim report January 1 – March 31, 2019
read more
Month: May 2019
Communiqué from the Annual General Meeting of EMOTRA AB (publ)
The Annual General Meeting of EMOTRA AB (publ) was held today, May 15, 2019. The resolutions, summarised below, were all adopted with the necessary majority. 190515 - Emotra- PM - Communiqué from AGM
EDOR® Test Identifies Patients with a Higher Risk of Depression Relapse
Emotra has previously announced that new research results have indicated new application areas for Emotra’s method, EDOR. These areas open new possibilities for widening the method’s use in clinical practice. We can now reveal that the application in question concerns...
Emotra is granted a patent in the USA
The US will be one of Emotra’s priority markets in the future. We have earlier announced that the Company has applied for patents in the EU, USA, Canada and Japan and patents have been granted in Sweden and Japan. The US patent office has now informed us that Emotra’s...